Chronic Obstructive Pulmonary Disease | Access and Reimbursement | US | 2018
The chronic obstructive pulmonary disease (COPD) market is experiencing increased competition as newer combination therapies vie with long-marketed stalwarts Spiriva, Advair, and Symbicort. Current treatment includes several distinct drug classes with emerging therapies in the pipeline. Because of the age of patients with COPD, market access is driven by Medicare-related payers such as Medicare Advantage and Part D plans that leverage competition to extract rebates from industry in exchange for preferred coverage. By 2021, additional therapies for COPD will increase options and competition, but generic erosion of blockbuster agents will influence reimbursement decisions.
QUESTIONS ANSWERED
- What actions can marketers of COPD therapies take to succeed in terms of market access and thus increase overall sales? How do physicians, payers, patients, and industry interact to influence treatment decisions?
- What factors, including those tied to market access, influence physician prescribing of select COPD therapies, and what therapies are succeeding and stumbling based on these factors?
- How do Medicare Advantage payers reimburse and restrict access to select COPD therapies, and what factors are driving their reimbursement decisions? How are pharmacoeconomic models being used in reimbursement decisions for COPD therapies and what is the impact on industry?
- What factors will have the most sway in determining the success of emerging therapies like revefancin and glycopyrrolate? How do payers intend to reimburse emerging agents, and how will those decisions affect prescribing?
Related Market Assessment Reports
Report
Scleroderma (Systemic Sclerosis) – Current Treatment – Treatment Algorithms: Claims Data Analysis – Scleroderma (Systemic Sclerosis) (US)
Scleroderma (systemic sclerosis) (SSc) is a rare progressive autoimmune disorder characterized by skin fibrosis, systemic inflammation, and vasculopathy that can manifest as Raynaud’s phenomenon…
Report
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Geographic Focus: China – Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – China In-Depth (China)
The NHL therapy market in China is poised for significant growth over the next decade, driven by the introduction of novel therapies and the continued uptake and label expansion of premium-priced…
Report
Hypertrophic Cardiomyopathy – Current Treatment – Treatment Algorithms: Claims Data Analysis – Hypertrophic Cardiomyopathy (US)
HCM is a genetic heart condition characterized by thickened myocardium and left ventricular hypertrophy, often linked to sarcomere mutations. While some patients remain asymptomatic, common…
Report
Non-Small-Cell Lung Cancer – Geographic Focus: China – China In-Depth – Non-Small-Cell Lung Cancer
Non-small-cell lung cancer (NSCLC) is the leading cause of cancer-related mortality in China. Treatment is based on biomarker status; patients with EGFR- and ALK-positive tumors generally receive…
